News
NanoViricides Reports Breakthrough in Treating Airborne Viruses, Boosting Lifespan in Infected Mice
8 May 24
News
EF Hutton Reiterates Buy on Nanoviricides, Maintains $6.5 Price Target
7 May 24
News, Price Target, Reiteration, Analyst Ratings
12 Health Care Stocks Moving In Monday's Intraday Session
6 May 24
Movers
NanoViricides' Broad-Spectrum Antiviral NV-387 Offers Protection Against Influenza A and Bird Flu
6 May 24
News
EF Hutton Reiterates Buy on Nanoviricides, Maintains $6.5 Price Target
16 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Nanoviricides Q2 EPS $(0.18) Down From $(0.15) YoY; As Of December 31, 2023, We Had Cash And Cash Equivalent Current Assets Balance Of Approximately $5.31M. Additional Agreements Have Resulted In A Further Approximately $2.5M Available Cash
15 Feb 24
Earnings, News
Press releases
NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City
10 May 24
Events, Press Releases
A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
8 May 24
News, Press Releases
A Novel Broad-Spectrum Antiviral with Activity Against Influenza A
6 May 24
News, Press Releases
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
30 Apr 24
News, Press Releases
NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
15 Feb 24
Earnings, Press Releases